Engineered Mesenchymal Stem Cell‐Derived Extracellular Vesicles as Antifibrotic Nanotherapeutics for Chronic Kidney Disease
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71577 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Wen Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Mesenchymal Stem Cells, Renal Insufficiency, Chronic, Nanomedicine. Die Arbeit nennt 149 Literaturangaben. Gefördert von: Plan Project of Zhejiang Provincial Hospital of Traditional Chinese Medicine Administration, Hangzhou Science and Technology Bureau.
Abstract (Originalsprache)
Chronic kidney disease (CKD) affects more than 850 million people worldwide, and progressive renal fibrosis is the most common cause of irreversible renal loss. Mesenchymal stem cell‐derived extracellular vesicles (MSC‐EVs) are nanoscale membrane‐bound particles carrying bioactive proteins, lipids, and regulatory RNAs across biological barriers. Target cells are EVs that enter via membrane receptors and endocytic/fusion pathways and provide cargo delivery and modulation of downstream signaling. Engineering techniques such as genetic modification of parent cells, chemical surface functionalization, stimuli‐responsive materials, and synthetic materials have improved the therapeutic potential of MSC‐EVs by improving tissue targeting and antifibrotic activity. This review summarizes MSC‐EV colloidal biology, biogenesis, surface properties, cargo composition, and engineered modifications for antifibrotic applications. Mechanisms that inhibit fibrosis, such as suppression of the TGF‐β/Smad pathway, reversal of epithelial–mesenchymal transition, and modulation of macrophage behavior at the tissue–vesicle interface, are discussed. Effects of donor cell preconditioning and microenvironmental factors on surface properties and therapeutic potency are discussed. This paper is a paradigm shift from traditional biology to precision nanomedicine engineering using colloidal surface chemistry, biointerface dynamics, and translational manufacturing. We bridge material science with renal pathophysiology to develop a rational roadmap for future clinically available EV therapeutics targeting multifactorial renal fibrotic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
- Pujiang Branch, The First Affiliated Hospital of Zhejiang University, Zhejiang, China.
- Department of Nephrology, Jiangshan Hospital of Traditional Chinese Medicine, Zhejiang, China.
- Department of Nephrology, Hangzhou Medical College Affiliated Lin'an People's Hospital, Hangzhou, China.
ORCID-Profile: Wen Zhang, Zhijian Cao, Xiaoran Wang
Förderung
- Plan Project of Zhejiang Provincial Hospital of Traditional Chinese Medicine Administration
- Hangzhou Science and Technology Bureau
Zitieren
APA
Zhang, W., Xu, S., Cao, Z., Jin, W., Deng, S., Zhou, Q., Xia, X., & Wang, X. (2026). Engineered Mesenchymal Stem Cell‐Derived Extracellular Vesicles as Antifibrotic Nanotherapeutics for Chronic Kidney Disease. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71577
Vancouver
Zhang W, Xu S, Cao Z, Jin W, Deng S, Zhou Q, et al. Engineered Mesenchymal Stem Cell‐Derived Extracellular Vesicles as Antifibrotic Nanotherapeutics for Chronic Kidney Disease. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71577
BibTeX
@article{Zhang2026,
author = {Zhang, Wen and Xu, Sumei and Cao, Zhijian and Jin, Wen and Deng, Shihu and Zhou, Qiuju and Xia, Xiaofan and Wang, Xiaoran},
title = {Engineered Mesenchymal Stem Cell‐Derived Extracellular Vesicles as Antifibrotic Nanotherapeutics for Chronic Kidney Disease},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71577}
}
EUVIMED